Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

ZEVALIN

IBRITUMOMAB TIUXETAN

Standard Dose
3.2MG/2ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ZEVALIN is listed in Drugs@FDA under application 125019 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient IBRITUMOMAB TIUXETAN Form and strength INJECTABLE; INJECTION - 3.2MG/2ML Sponsor SPECTRUM PHARMS Submission history Latest submission status date: 2018-12-11 00:00:00.

Structured Monograph

Clinical summary

Approval overview ZEVALIN is listed in Drugs@FDA under application 125019 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient IBRITUMOMAB TIUXETAN Form and strength INJECTABLE; INJECTION - 3.2MG/2ML Sponsor SPECTRUM PHARMS Submission history Latest submission status date: 2018-12-11 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.